Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,890 recruiting studies in this area right now.
By phase
- Not applicable4,918
- Phase 21,185
- Phase 1582
- Phase 3465
- Phase 1/Phase 2393
- Phase 4236
- Phase 2/Phase 3111
Top conditions
- Colorectal Cancer491
- Gastric Cancer296
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Esophageal Cancer191
- Rectal Cancer176
- Breast Cancer146
- Crohn Disease144
- Ulcerative Colitis141
- Colon Cancer115
- Inflammatory Bowel Diseases108
- Hepatocellular Carcinoma (HCC)106
- Liver Cancer100
- Lung Cancer97
- Pancreas Cancer94
- Esophageal Squamous Cell Carcinoma88
- Ovarian Cancer88
- Cystic Fibrosis78
Leading sponsors
- Fudan University104
- Sun Yat-sen University90
- Mayo Clinic75
- Chinese University of Hong Kong60
- M.D. Anderson Cancer Center58
- Second Affiliated Hospital, School of Medicine, Zhejiang University57
- Assistance Publique - Hôpitaux de Paris55
- Sixth Affiliated Hospital, Sun Yat-sen University50
- National Taiwan University Hospital49
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences48
Where studies are running
- California461
- Arizona177
- Texas149
- Florida133
- Massachusetts128
- New York123
- Alabama122
- Maryland86
- Ohio80
- Pennsylvania72
Recruiting studies7,890 total
- NCT05652621Recruiting
Probiotics for people with ulcerative colitis symptoms
This study looks at whether probiotic pellets help people with inflammatory bowel disease, specifically ulcerative colitis. It may help improve gut symptoms, but the trial will test how well probiotics work for participants like you.
Xinxiang, HenanAges 18–80 - NCT05653011Recruiting
Study outcomes in people with inflammatory bowel disease
This study looks at what factors help predict how inflammatory bowel disease (IBD) may progress over time. You may be able to join if you are an adult with IBD and fit one of the study groups based on whether you have used TNF-blocking medicines before.
Seongnam-si, Gyeonggi-doAges 18 years+ - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05655494Recruiting
Helping underrepresented people find cancer clinical trials
This study tests an approach to help people from groups historically underrepresented in cancer trials learn about and connect to clinical trials. It may help you get easier, more personal ways to be contacted about research options.
Gainesville, FloridaAges 18–100 - NCT05655780Recruiting
Irinotecan care guided by tumor genes and gut bacteria
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
Maastricht, LimburgAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05657743Recruiting
Radiation seeds study for advanced pancreatic cancer safety
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
HolonAges 18 years+ - NCT05658081Recruiting
Two surgical stitch methods for Crohn’s bowel surgery
This trial compares two surgical ways of connecting the bowel in people with Crohn’s disease who need bowel resection (removal of a diseased bowel segment) and then reconnect it. If you qualify, the study may help show which method is safer or leads to better recovery.
Nanjing, JiangsuAges 16–60 - NCT05660746RecruitingPhase 2/Phase 3
Infliximab dose tailored to control Crohn’s inflammation
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Los Angeles, CaliforniaAges 6–22 - NCT05661643RecruitingPhase 2
Temozolomide for GIST tumors with SDH deficiency
This trial tests how well temozolomide works and how safe it is for people with GIST (a type of stomach/intestine tumor) that is SDH-deficient and has no KIT or PDGFRα mutations. It may help by targeting tumor DNA repair weakness seen in this SDH-deficient subtype.
Seoul, SeoulAges 20 years+ - NCT05661786Recruiting
Study outcomes for hepatitis B with “indeterminate” disease phase
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Changzhou, JiangsuAges 18 years+ - NCT05663203Recruiting
Web-based support program for colorectal cancer patients and caregivers
This trial tests a web-based coaching/support program done together by you and your main caregiver. It may help by addressing common emotional and brain-related symptoms during active chemotherapy.
Atlanta, GeorgiaAges 18 years+ - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
La Jolla, CaliforniaAges 18 years+ - NCT05663515Recruiting
Checks pancreatic cancer risk after starting exenatide in type 2 diabetes
This study looks at whether starting exenatide (a type 2 diabetes medicine) is linked to a higher or lower risk of pancreatic cancer compared with other similar diabetes medicines. It uses people’s prescription and medical record history to compare risks over time.
CopenhagenAges 18–99 - NCT05666609Recruiting
Study of anal fistula care in infants and children
This study includes babies and children (ages 0–18) who have an anal fistula and receive a specific kind of treatment called a non-cutting seton. It aims to better understand fistula-in-ano care using this approach in young patients.
Erlangen, BavariaAges Up to 18 years - NCT05666960RecruitingPhase 1
Study drug R-3750 for mild to moderate ulcerative colitis
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
Valencia, CaliforniaAges 18–65 - NCT05667805RecruitingPhase 4
Testing blood clotting in people with liver cirrhosis
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
ViennaAges 18 years+ - NCT05669339RecruitingPhase 2
AI-guided dosing study for advanced liver cancer patients
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Gainesville, FloridaAges 18–99 - NCT05670951RecruitingPhase 3
Drug ELGN-2112 for gut absorption problems in preterm babies
This Phase 3 trial tests whether ELGN-2112 helps preterm babies absorb food from the intestines. It aims to improve intestinal malabsorption and check safety.
NetanyaAges 1 day–5 days - NCT05672108RecruitingPhase 2
Chemo delivered into lung tumors using a catheter
This trial studies a treatment that delivers chemotherapy directly to lung tumors by placing a catheter into lung blood vessels. It may help people with lung cancer or lung metastases that are growing despite standard treatment, or who cannot tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05674643Recruiting
Gastric testing during children’s surgery
This trial studies how the stomach is working in children around the time of surgery. It may help improve how doctors assess and manage stomach function to make surgery safer and more comfortable.
Boston, MassachusettsAges 2–18 - NCT05676190Recruiting
Cell therapy using your own immune cells for colorectal cancer
This trial studies an immune cell treatment made from your own blood cells to treat colorectal cancer that has spread or progressed. You may be eligible if you have stage III–IV disease that can be measured on scans and if standard treatments have not worked or couldn’t be tolerated.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Birmingham, AlabamaAges 18–75
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,890 recruiting gastroenterology studies from the U.S. registry right now, out of 12,399 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.